(Q36895839)

16 August 2017

1 reference

title

A comparative evaluation of properties and clinical efficacy of the echinocandins (English)

1 reference

16 August 2017

Rose Kim

1

1 reference

16 August 2017

Deborah Khachikian

series ordinal

2

1 reference

16 August 2017

Annette C Reboli

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

10

1 reference

16 August 2017

page(s)

1479-1492

1 reference

Echinocandin antifungal drugs

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Echinocandins in the management of invasive fungal infections, part 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Pharmacokinetics/pharmacodynamics of echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Caspofungin: a review of its use in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Echinocandins: role in antifungal therapy, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Potential for interactions between caspofungin and nelfinavir or rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1479

10.1517/14656566.8.10.1479

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference